TFRC and acute myeloid leukemia: The expression level of TFRC was increased when AML cells were treated with AVA (Avapritinib, Fig. 6f) or Ara-C + ABT199 (Ara-C combined with ABT199, Fig. 6g), while the expression level of TFRC was decreased when AML cells were treated with gilteritinib (GSE199333, Fig. 6h) or homoharringtonine (GSE182020, Fig. 6i).